Exponent (EXPO) has caught investor attention after its recent share price move, with the stock up 3.6% over the past week and about 11.5% over the past month based on provided data.

Zooming out, Exponent’s recent 90 day share price return of 22.52% contrasts with a year to date share price move that is roughly flat. The 3 year and 5 year total shareholder returns show declines, which suggests momentum has picked up only in the shorter term as investors reassess growth prospects and risks around the current US$69.91 share price.

If you are curious about what else could be moving next, this can be a good moment to widen your search and check out 21 top founder-led companies

After Exponent’s recent rebound, the stock trades at about US$69.91 while analyst targets and intrinsic value estimates point higher. How wide is that valuation gap in reality, and what does it suggest about today’s price?

Most Popular Narrative: 14.4% Undervalued

Exponent’s most followed narrative anchors on a fair value of about $81.67 per share, compared with the recent $69.91 close, which frames the current gap investors are debating.

Ongoing expansion into high-growth, innovation-driven domains, including artificial intelligence safety, distributed energy systems, and advanced medical technologies, broadens Exponent's addressable market and client base, setting up an accelerating revenue trajectory as these industries scale.

Strengthening headcount growth, propelled by effective recruiting and a development-focused culture, enables Exponent to capture more project volume and maintain its reputation-driven pricing power, with positive implications for both top-line growth and sustained high net margins.

Want to understand why this narrative tags Exponent as undervalued at a double digit discount to fair value? The entire case leans on steady revenue expansion, resilient margins and a future earnings multiple that assumes investors will still pay up for this consulting model.

Result: Fair Value of $81.67 (UNDERVALUED)

However, Exponent’s flat net revenues, along with lower EBITDA and declining utilization, suggest that weaker project flow or rising costs could quickly challenge this undervalued narrative.

Another View On Exponent’s Valuation

While the narrative around Exponent focuses on a fair value of about $81.67, the current P/E of 29.7x is well above both the estimated fair ratio of 17.4x and the peer average of 20.1x. That gap implies investors are paying up today. Is that premium a source of comfort or a source of risk for you?

Next Steps

The mix of optimism and caution around Exponent is clear, so do not wait to check the details for yourself. To see what is driving that optimism, review the 5 key rewards.

Looking for more investment ideas beyond Exponent?

Do not stop with Exponent. Use the Simply Wall Street Screener to uncover fresh opportunities that match your style before someone else acts on them.

• Target higher income potential by reviewing companies in the 12 dividend fortresses that may suit a yield focused portfolio.
• Spot potential value opportunities by scanning the 52 high quality undervalued stocks and see which stocks currently trade below their estimated worth.
• Prioritise resilience by checking the 78 resilient stocks with low risk scores so you can focus on companies with lower overall risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.